edgen-logo

AI Copilot
portfolioPortfolio

Stocks

Crypto

News
StocksCrypto

Chat History

Aura
Follow our

Join our

EN
Back

AbbVie Secures Extended Patent Protection for Key Drug RINVOQ
Stock NewsThemesAbbVie Secures Extended Patent Protection for Key Drug RINVOQ

AbbVie Secures Extended Patent Protection for Key Drug RINVOQ

Edgen StockEdgen Stock·Sep 11 2025, 21:36
Share to
Share to
Copy link
ABBVABBV+1.80%
AbbVie Secures Extended Patent Protection for Key Drug RINVOQ
source:
[1] Why AbbVie (ABBV) Stock Is Trading Up Today (https://finance.yahoo.com/news/why-abbvie-abb ...)[2] AbbVie: What's Happening With ABBV Stock? - Forbes (https://vertexaisearch.cloud.google.com/groun ...)[3] AbbVie settles with generic drugmakers for key immunology drug Rinvoq - Seeking Alpha (https://seekingalpha.com/news/4054900-abbvie- ...)

Related News

Babcock & Wilcox Secures $40M Refinery Contract
Dec 19 2025, 22:38

Babcock & Wilcox Secures $40M Refinery Contract

Babcock & Wilcox announced on December 19, 2025, that it secured a $40 million contract to supply its Wet Gas Scrubbing technology to a Canadian petroleum refinery, major Canadian petroleum refinery.

Tesla Profits Plunge 53% as Politics Cost 1.26M Sales
Dec 19 2025, 22:29

Tesla Profits Plunge 53% as Politics Cost 1.26M Sales

A Yale study finds Elon Musk's political stance cost Tesla 1.26 million car sales, contributing to a profit drop to $7.1 billion in 2024 from $15 billion in 2023.

Mizuho Lifts Tesla Target to $530 on Robotaxi Hopes
Dec 19 2025, 22:27

Mizuho Lifts Tesla Target to $530 on Robotaxi Hopes

On December 16, Mizuho increased its price target for Tesla to $530, citing growing confidence in the automaker's future robotaxi business.